We conducted a randomized controlled trial to assess the efficacy of darapladib, a specific oral inhibitor of Lp-PLA2, in treating silica-induced pulmonary fibrosis in mice (Fig. 8a). The gene discussed is PLA2G7; the disease is pulmonary fibrosis.